Sellas Life Sciences SLS
$13.66 −$1.20 (-8.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $14.21 +4.03%
Open$14.98
Prev close$14.86
Day range$13.39 – $15.19
Volume15.48M
Market cap$2.78B
P/E (TTM)–
Dividend yield–
SLS Stock News
Headlines matching Sellas Life Sciences or the SLS ticker, most recent first.
- Sims Ltd: SLS Investor Day Presentation
- Solstice Minerals Ltd: Application for quotation of securities - SLS
- Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
- Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, Vs. FactSet Est of $0.05 Loss Negative
- Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $30 Positive
- A. G. P. Initiates Sellas Life Sciences(SLS.US) With Buy Rating, Announces Target Price $25
- Pre-Market Movement | SLS.US Stock Price Fluctuates Amid Multiple News Items
- Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
- A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
- A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10 Positive
- Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10 Positive
- Solstice Minerals Ltd: Application for quotation of securities - SLS
- Sims Ltd: Appointment of Tiffany Osias as President of SLS
- Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
- Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold Surge Positive
No comments yet — be the first to weigh in on SLS.
Sign in to join the discussion.